Skip to main content
PDSB
NASDAQ Life Sciences

PDS01ADC Shows 78% ORR, >80% 2-Year Survival in mCRC Phase 2 Trial, Data Published

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.08
Mkt Cap
$59.165M
52W Low
$0.507
52W High
$1.915
52W Position info
113% above low
Off High info
44% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PDSB has more than doubled off its 52-week low of $0.507.

Summary

PDS Biotech announced the publication of positive interim Phase 2 clinical trial data for its PDS01ADC in metastatic colorectal cancer (mCRC). Data from Stage 1 (N=9) of an NCI-led trial showed a 78% objective response rate (ORR) and an approximate 85% 2-year survival rate. These results compare favorably to a parallel trial without PDS01ADC, which had a 35% ORR and ~40% 2-year survival rate. This is highly significant as the trial targets unresectable MSS or pMMR mCRC, a patient population where immune checkpoint inhibitors have been largely ineffective. For a small-cap immunotherapy company, these strong efficacy signals, published in a reputable journal, represent a material de-risking event and could lead to substantial investor interest and stock price movement. Investors will now watch for further trial progression, including Stage 2 data, and potential strategic developments.

At the time of this announcement, PDSB was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.2M. The 52-week trading range was $0.51 to $1.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PDSB - Latest Insights

PDSB
Nov 13, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9822
Real-time Price: $0.8622 info
Change: -$0.120 (-12%) info
Market Cap: $91.628M info
PDSB
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.8622 info
Change: -$0.2178 (-20%) info
Market Cap: $91.628M info
PDSB
Oct 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9521
Real-time Price: $0.8622 info
Change: -$0.0899 (-9%) info
Market Cap: $91.628M info
PDSB
Oct 14, 2026, 4:17 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.8622 info
Change: -$0.5478 (-39%) info
Market Cap: $91.628M info
PDSB
Sep 22, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8334
Real-time Price: $0.8622 info
Change: +$0.0288 (+3%) info
Market Cap: $91.628M info